SEC Form 4 · accession 0001193125-26-276046
BridgeBio Oncology Therapeutics, Inc. · BBOT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter F Lebowitz
Director
Period of report
Jun 16, 2026
Accepted (ET)
Jun 18, 2026 · 4:57 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001869105
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $7.73 | Jun 16, 2026 | A | 7,289 | A | — | Jun 15, 2036 | Common Stock | 7,289 | 7,289 | D |
Explanation of responses
- F1The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.
Remarks
Exhibit 24 - Power of Attorney